Multivariate analysis of freedom from progression
. | No. patients . | Risk ratio*(95% CI) . | P . |
|---|---|---|---|
| CD8+ T-cell dose | |||
| At or above 50th percentile | 31 | 0.2 (0.1-0.6) | .003 |
| Below 50th percentile | 25 | 1.0 | NA |
| Advanced disease | |||
| Yes | 20 | 0.4 (0.2-1.0) | .06 |
| No | 36 | 1.0 | NA |
| Chronic GVHD, extensive | |||
| Yes | 20 | 0.3 (0.1-1.2) | .09 |
| No | 36 | 1.0 | NA |
. | No. patients . | Risk ratio*(95% CI) . | P . |
|---|---|---|---|
| CD8+ T-cell dose | |||
| At or above 50th percentile | 31 | 0.2 (0.1-0.6) | .003 |
| Below 50th percentile | 25 | 1.0 | NA |
| Advanced disease | |||
| Yes | 20 | 0.4 (0.2-1.0) | .06 |
| No | 36 | 1.0 | NA |
| Chronic GVHD, extensive | |||
| Yes | 20 | 0.3 (0.1-1.2) | .09 |
| No | 36 | 1.0 | NA |
Patients not evaluable for chronic graft-versus-host disease were excluded from analysis for both covariates. NA indicates not applicable.
GVHD indicates graft-versus-host disease.
Risk ratio value indicates likelihood of death and/or disease progression (progression-free survival) with, respectively, indicated CD8+ T-cell dose or presence of chronic graft-versus-host disease